키모맵 테라퓨틱스 ADRCMMB 주가

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

—New Clinical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Additional Benefit in PSC Patients with Co-Existing IBD— —Company Continues to Advance Multiple Partnering Options for Nebokitug— TEL AVIV, Israel, May 14, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics

Chemomab Therapeutics Q1 EPS $(0.24) Beats $(0.31) Estimate

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.31) by 22.58 percent. This is a 57.14 percent increase over losses of $(0.56) per share

[6-K] 6-K — 6-K

[6-K] 6-K — 6-K

[6-K] 6-K — 6-K

[3] 3

[3] 3

[3] 3

[3] 3

[3] 3 — FORM 3